|
業務類別
|
Biotechnology |
|
業務概覽
|
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1. |
| 公司地址
| 628 Middlefield Road, Palo Alto, CA, USA, 94301 |
| 電話號碼
| +1 650 249-2727 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.kalaristx.com |
| 員工數量
| 6 |
| Mr. Andrew Oxtoby |
President and Chief Executive Officer, Director |
-- |
01/07/2025 |
| Mr. Brett R. Hagen |
Chief Accounting Officer |
-- |
01/07/2025 |
| Dr. Matthew Feinsod |
Chief Medical Officer |
-- |
01/07/2025 |
|
|
| Mr. Andrew Oxtoby |
President and Chief Executive Officer, Director |
01/07/2025 |
| Ms. Leone D Patterson |
Director |
04/04/2025 |
| Dr. Morana Jovan-Embiricos, PhD |
Independent Director |
01/07/2025 |
| Mr. David L. Hallal |
Chairman of the Board |
01/07/2025 |
| Mr. Napoleone Ferrara, M.D. |
Independent Director |
01/07/2025 |
| Dr. Anthony P. Adamis, M.D. |
Independent Director |
01/07/2025 |
| Dr. Michael Dybbs, PhD |
Director |
01/07/2025 |
| Dr. Srinivas Akkaraju, M.D.,PhD |
Director |
01/07/2025 |
|
|
|
|
